Nucleic acids encoding lectin-like oxidized LDL receptor 1 antibodies
AssigneeNovartis AG
InventorsKurt Alex Heldwein, Igor Splawski, Jennifer Brogdon, Joshua Goldstein, William Dole, John Trauger, Chonghui Zhang
Life of this patent
Estimating the term…
Abstract
The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
Claims24
A nucleic acid encoding an antibody or antigen binding fragment thereof which specifically binds to human lectin-type oxidized low density lipoprotein receptor 1 (LOX-1), wherein said antibody or fragment comprises a heavy chain variable region (VH) comprising complementarity determining regions HCDR1, HCDR2, and HCDR3, and a light chain variable region (VL) comprising complementarity determining regions LCDR1, LCDR2, and LCDR3, and wherein the HCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NO:
- 8, 28, 48, 68, and 88;
- the HCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO:
- 9, 29, 49, 69, and 89;
- the HCDR3 comprises an amino acid sequence selected from the group consisting of 10, 30, 50, 70, and 90;
- the LCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NO:
- 18, 38, 58, 78, and 98;
- the LCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO:
- 19, 39, 59, 79, and 99;
- and the LCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NO:
- 20, 40, 60, 80, and 100.
A nucleic acid encoding an antibody or antigen binding fragment thereof which specifically binds to human lectin-type oxidized low density lipoprotein receptor 1 (LOX-1), wherein said antibody or fragment comprises a heavy chain variable region comprising complementarity determining regions HCDR1, HCDR2, and HCDR3 and a light chain variable region comprising complementarity determining regions LCDR1, LCDR2, and LCDR3, wherein the HCDR1 comprises the amino acid sequence of SEQ ID NO:
- 8;
- the HCDR2 comprises the amino acid sequence of SEQ ID NO:
- 9;
- the HCDR3 comprises the amino acid sequence of SEQ ID NO:
- 10;
- the LCDR1 comprises the amino acid sequence of SEQ ID NO:
- 18;
- the LCDR2 comprises the amino acid sequence of SEQ ID NO:
- 19;
- and the LCDR3 comprises the amino acid sequence of SEQ ID NO:
- 20.
A nucleic acid encoding an antibody or antigen binding fragment thereof which specifically binds to human LOX-1, wherein said antibody or fragment comprises a VH comprising complementarity determining regions HCDR1, HCDR2, and HCDR3, and a VL comprising complementarity determining regions LCDR1, LCDR2, and LCDR3, and wherein the HCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NO:
- 11, 31, 51, 71, and 91;
- the HCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO:
- 12, 32, 52, 72, and 92;
- the HCDR3 comprises an amino acid sequence selected from the group consisting of 13, 33, 53, 73, and 93;
- the LCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NO:
- 21, 41, 61, 81, and 101;
- the LCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO:
- 22, 42, 62, 82, and 102;
- and the LCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NO:
- 23, 43, 63, 83, and 103.
Dependencies are inferred from the claim text.